Identification of mouse AAV capsid-specific CD8+ T cell epitopes

Slides:



Advertisements
Similar presentations
Fig. 1. Level of Mac-1 expression on naive and recently activated LCMV GP33–41-specific T cells from TCR 318 transgenic mice. (A and B) Splenocytes from.
Advertisements

Volume 10, Issue 2, Pages (August 2004)
Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice  Ying Wang,
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells by Federico Mingozzi, Janneke.
Volume 25, Issue 10, Pages (October 2017)
Volume 25, Issue 2, Pages (February 2017)
Ting-ting Zhang, MSc, Klaus Okkenhaug, PhD, Baher F
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
by Éric Aubin, Réal Lemieux, and Renée Bazin
CXCL12 enhances exogenous CD4+CD25+ T cell migration and prevents embryo loss in non-obese diabetic mice  Yi Lin, M.D., Liang Xu, M.D., Haiyan Jin, M.D.,
Volume 25, Issue 11, Pages (November 2017)
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.
Volume 15, Issue 8, Pages (August 2007)
CpG Methylation of a Plasmid Vector Results in Extended Transgene Product Expression by Circumventing Induction of Immune Responses  A. Reyes-Sandoval,
Volume 22, Issue 5, Pages (May 2014)
Volume 18, Issue 5, Pages (May 2003)
Characterization of natural killer cells in nonobese diabetic/severely compromised immunodeficient mice during pregnancy  Yi Lin, M.D., Yanmin Zhong,
Volume 15, Issue 2, Pages (February 2007)
Volume 13, Issue 1, Pages (January 2006)
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity  Zhang-Xu Liu, Sugantha Govindarajan,
Volume 19, Issue 11, Pages (November 2011)
The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed by Jelena Popović, Liang-Ping Li, Peter Michael Kloetzel,
Confirmation of novel RSV CD8+ T cell epitopes.
Volume 23, Issue 10, Pages (October 2015)
Volume 25, Issue 4, Pages (April 2017)
Volume 26, Issue 9, Pages (September 2018)
Volume 13, Issue 6, Pages (December 2000)
Volume 15, Issue 2, Pages (February 2007)
Role of B cells in TH cell responses in a mouse model of asthma
Volume 22, Issue 1, Pages (January 2014)
Activation of Akt as a Mechanism for Tumor Immune Evasion
Volume 13, Issue 2, Pages (February 2006)
Immunopathology in RSV Infection Is Mediated by a Discrete Oligoclonal Subset of Antigen-Specific CD4+ T Cells  Steven M Varga, Xiaoting Wang, Raymond.
Volume 21, Issue 1, Pages (January 2013)
RSV peptide library screen for candidate CD4+ T cell epitopes.
Volume 12, Issue 5, Pages (November 2005)
Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node  Lifang Cheng,
Volume 13, Issue 2, Pages (February 2006)
Volume 24, Issue 4, Pages (April 2016)
Volume 17, Issue 2, Pages (February 2009)
Volume 25, Issue 1, Pages (January 2017)
Volume 29, Issue 4, Pages (October 2008)
Volume 18, Issue 7, Pages (July 2010)
Volume 24, Issue 1, Pages (January 2016)
Volume 19, Issue 6, Pages (June 2011)
Matthew A. Williams, Eugene V. Ravkov, Michael J. Bevan  Immunity 
Volume 8, Issue 2, Pages (August 2003)
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
Volume 8, Issue 1, Pages (July 2003)
Ag 85A–specific immune responses.
Volume 17, Issue 5, Pages (May 2009)
Volume 25, Issue 10, Pages (October 2017)
Defining antigen-specific responses with human MHC class II tetramers
Volume 17, Issue 10, Pages (October 2009)
Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand  Yelena Glinka,
Attrition of T Cell Memory
Volume 20, Issue 3, Pages (March 2012)
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Volume 25, Issue 4, Pages (April 2017)
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity  Tomer Granot,
Members of IL-1 family of cytokines favor the generation of IL-3–secreting CD4+ T cells in vitro. Members of IL-1 family of cytokines favor the generation.
Volume 25, Issue 5, Pages (May 2017)
Molecular Therapy - Methods & Clinical Development
Sang Kyun Ahn, Vanessa Tran, Andrea Leung, Mark Ng, Ming Li, Jun Liu 
Volume 27, Issue 8, Pages (August 2019)
Memory CD8+ T Cells Undergo Peripheral Tolerance
Volume 12, Issue 5, Pages (November 2005)
Volume 25, Issue 4, Pages (April 2017)
Volume 25, Issue 2, Pages (February 2017)
Presentation transcript:

Identification of mouse AAV capsid-specific CD8+ T cell epitopes Denise E. Sabatino, Federico Mingozzi, Daniel J. Hui, Haifeng Chen, Peter Colosi, Hildegund C.J. Ertl, Katherine A. High  Molecular Therapy  Volume 12, Issue 6, Pages 1023-1033 (December 2005) DOI: 10.1016/j.ymthe.2005.09.009 Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Identification of the AAV-2 capsid epitope in C57BL/6 mice. (A) Intracellular cytokine staining of cells from C57BL/6 mice immunized with Ad-AAV-2 capsid. Cells were incubated with no peptide (negative control), six pools of peptides, and PMA/ionomycin (positive control) (not shown) to identify pool F as containing epitopes. Staining was done using an anti-mouse CD8+ antibody conjugated to FITC and an anti-mouse IFN-γ antibody conjugated to PE to determine frequencies of IFN-γ-producing CD8+ T cells by flow cytometry analysis. The % in each data plot represents the percentage of CD8+ T cells that secreted IFN-γ. (B) Intracellular cytokine staining of matrix pools of peptides from pool F. Eleven matrix pools were screened to identify the individual peptides that contain the epitope. (C) Matrix of pool F. Matrix pools 4, 5, and 10 implicate peptides 140 (PEIQYTSNYNKSVNV) and 141 (TSNYNKSVNVDFTVD) as containing the epitope. (D) To identify the epitope (9-mer), a panel of seven 9-mers offset by one amino acid was screened to identify SNYNKSVNV as the epitope. No peptide (negative control) and PMA/ionomycin (positive control) (36.6%) are shown. *Positive peptide. Molecular Therapy 2005 12, 1023-1033DOI: (10.1016/j.ymthe.2005.09.009) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Identification of the AAV-2 capsid epitope in BALB/c mice. (A) ICS performed on cells from BALB/c mice immunized with Ad-AAV-2 capsid. Six pools containing the AAV-2 capsid peptide library were screened to identify one positive pool (pool D). (B) A matrix of pool D implicated peptides 74 and 75 as containing an epitope (data not shown). This was followed by a screen of 9-mers derived from the positive 15-mer sequences. The negative control was no peptide and the positive control was PMA/ionomycin (41.1%) (data not shown). Peptide VPQYGYLTL had the most robust response and represents the epitope. Staining was done using an anti-mouse CD8+ antibody conjugated to FITC and an anti-mouse IFN-γ antibody conjugated to PE to determine frequencies of IFN-γ-producing CD8+ T cells by flow cytometry analysis. The % in each data plot represents the percentage of CD8+ T cells that secreted IFN-γ. Molecular Therapy 2005 12, 1023-1033DOI: (10.1016/j.ymthe.2005.09.009) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Identification of the AAV-8 capsid epitopes in C57BL/6 mice. (A) ICS was used to screen the entire AAV-8 peptide library using a matrix approach (data not shown). Eight peptides were screened individually by ICS. Staining was done using an anti-mouse CD8+ antibody conjugated to FITC and an anti-mouse IFN-γ antibody conjugated to PE. Peptides 171–174 had CD8+ T cells that were positive for IFN-γ after the initial screen. The % in each data plot represents the percentage of CD8+ T cells that secreted IFN-γ. (B) A panel of 9-mers contained within 171–174 was screened along with no peptide (negative control) and PMA/ionomycin (positive control) (21.8%), peptide 171–174 as a peptide pool, and the panel of 9-mers. This screen of 9-mers identified NSLANPGIA as having the most robust response. Molecular Therapy 2005 12, 1023-1033DOI: (10.1016/j.ymthe.2005.09.009) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 4 Identification of the AAV-8 capsid epitope in BALB/c mice. A peptide library was screened using a matrix approach to identify the AAV-8 capsid epitope in BALB/c mice. Peptides 124 and 125 were positive for IFN-γ secretion and CD8 after the screen of the matrix. Individual peptides (9-mers) were generated that are contained within the 124–125 peptide sequence and were screened along with no peptide (negative control), PMA/ionomycin (positive control) (data not shown), and the peptides 124 and 125 by ICS. Staining was done using an anti-mouse CD8+ antibody conjugated to FITC and an anti-mouse IFN-γ antibody conjugated to PE. The % in each data plot represents the percentage of CD8+ T cells that secreted IFN-γ. The peptide identified as the epitope with the most robust response was IPQYGYLTL. Molecular Therapy 2005 12, 1023-1033DOI: (10.1016/j.ymthe.2005.09.009) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 5 AAV-induced T cells cross-react with peptides for different serotypes. (A) BALB/c mice were immunized with Ad-AAV-2 capsid (top) or Ad-AAV-8 capsid (bottom). The splenocytes were harvested 9 days after immunization and were incubated with the identified epitope and the corresponding peptide sequence from the alternate serotype. That is, splenocytes from BALB/c mice immunized with Ad-AAV-2 were incubated with the AAV-2 epitope (VPQYGYLTL) and the corresponding AAV-8 peptide sequence (IPQYGYLTL). In this case the corresponding AAV-8 peptide sequence is also the AAV-8 capsid immunodominant epitope. (B) C57BL/6 mice were immunized with Ad-AAV-2 capsid (top) or Ad-AAV-8 capsid (bottom). The splenocytes from these mice were incubated with the identified epitope and the corresponding peptide sequence from the alternate serotype. (C) The specific peptide sequences used for the experiment are listed. Molecular Therapy 2005 12, 1023-1033DOI: (10.1016/j.ymthe.2005.09.009) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions

FIG. 6 Relative affinities of the AAV epitopes for the MHC I molecule as determined by concentration gradient. C57BL/6 and BALB/c mice were immunized with Ad-AAV-2 or Ad-AAV-8 and 9 days later ICS was performed on harvested splenocytes. The following peptide concentrations were analyzed: 5, 1, 0.2, 0.04, 0.008, 0.00016, 0.000032, and 0 μg/ml. The AAV-2 epitopes are identified as solid lines and the AAV-8 epitopes are identified as dashed lines. (A) Concentration gradient of C57BL/6 mouse AAV epitopes. The AAV-2 SNY (SNYNKSVNV) epitope had a high relative affinity, whereas the AAV-2 NGR (NGRDSLVNPGPAMAS) epitope did not demonstrate a pronounced affinity curve. The AAV-8 NSL (NSLANPGIA) epitope had a higher relative affinity than the AAV-8 LTS epitope (LTSEEEIKTTNPVAT); i.e., higher doses of peptides were needed to induce a response. (B) Concentration gradient of BALB/c AAV epitopes. The AAV-2 VPQ (VPQYGYLTL) epitope had higher relative affinity compared to the other epitopes, AAV-2 FRP (FRPKRLNFKLFNIQV) and AAV-2 HSQ (HSQSLDRLMNPLIDQ). The AAV-2 VPQ (VPQYGYLTL) and AAV-8 IPQ (IPQYGYLTL) epitopes that are homologous peptides had similar affinity for the MHC molecule. Molecular Therapy 2005 12, 1023-1033DOI: (10.1016/j.ymthe.2005.09.009) Copyright © 2005 The American Society of Gene Therapy Terms and Conditions